Holte, Denmark

Thomas Engelbrecht Norkild Jonassen



 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Thomas Engelbrecht Norkild Jonassen

Introduction: Thomas Engelbrecht Norkild Jonassen, an accomplished inventor based in Holte, Denmark, has made notable strides in the field of pharmaceutical sciences. His work focuses on developing innovative compounds that target specific biological processes, which have the potential to advance treatments for various medical conditions.

Latest Patents: Jonassen holds a patent for "Phenyl Pyrrole Aminoguanidine Derivatives." This invention involves phenyl pyrrole aminoguanidine derivatives of the general formula (I), including their tautomeric forms. The patent describes the application of these derivatives in treating diseases associated with melanocortin receptors or related systems, such as conditions influenced by melanocyte-stimulating hormones.

Career Highlights: Throughout his career, Jonassen has been associated with Action Pharma A/S, where he has contributed to the company's innovative research endeavors. His dedication to exploring new therapeutic approaches has solidified his reputation as an inventive force in the field.

Collaborations: Jonassen has collaborated with notable coworkers, including Arne Boman and Torbjorn Lundstedt. Together, they work to further the research and development of pharmaceutical innovations that can significantly impact patient care.

Conclusion: Thomas Engelbrecht Norkild Jonassen exemplifies the innovative spirit of modern inventors in the pharmaceutical industry. His patent for phenyl pyrrole aminoguanidine derivatives highlights his commitment to addressing complex diseases through targeted treatments. As he continues his work at Action Pharma A/S, Jonassen remains a crucial contributor to advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…